SURREY, England – The Center for Veterinary Medicine (CVM) of the US Food and Drug Administration (FDA) has granted ECO Animal Health Group plc a marketing authorization in the United States for Aivlosin 625 mg/g water soluble granules for swine. The company is a leader in developing, registering and marketing pharmaceutical products for animals.

FDA’s approval is ECO’s first in the US and marks an important step in the company’s continuing development of Aivlosin as a global veterinary product. Canada recently approved this formulation and further extends the marketing reach of Aivlosin, ECO’s patented macrolide antibiotic, which is used for the treatment of respiratory and enteric (gut) diseases in pigs and poultry. In 2010, ECO established a joint venture sales and marketing company, Pharmgate Animal Health LLC, to prepare for the launch of Aivlosin.